Immunic (IMUX) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 1.9% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -91.9% for IMUX. Satellos Bioscience is the larger company by market cap ($120.5 million vs $111.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | MSLE |
|---|---|---|
| Share price | $6.99 | $5.68 |
| Market cap | $111.01M | $120.51M |
| 1-day change | -5.41% | -2.07% |
| YTD return | +30.90% | -3.40% |
| 1-year return | +1.90% | -5.33% |
| 5-year return | -91.88% | -58.48% |
| EPS (TTM) | $-3.53 | $-2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-97.17M | $-24.87M |
| 52-week high | $17.43 | $13.40 |
| 52-week low | $5.06 | $5.44 |
| Distance from 52-week high | -59.90% | -57.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +508.73% | +325.53% |
| Average volume | 343.44K | 51.19K |
| Shares outstanding | 15.88M | 21.22M |
| Employees | 100 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
IMUX vs MSLE FAQ
Which is bigger, Immunic or Satellos Bioscience?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $120.51M compared with $111.01M for Immunic (IMUX).
Which stock has performed better over the past year, IMUX or MSLE?
IMUX returned +1.90% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.